Media Room Menu
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
May 14, 2020Sutimlimab targets C1-activated hemolysis in cold agglutinin disease (CAD)
-
May 13, 2020- Emerging data demonstrate commitment to advancing cancer care, including two fully in-house investigational compounds: a potential best-in-class oral SERD for breast cancer and a first-in-class anti-CEACAM5 antibody-drug conjugate for non-small cell lung cancer
-
May 12, 2020- IKEMA trial results released early based on recommendation of an Independent Data Monitoring Committee
-
May 7, 2020- Company on Track to Complete Submission of Rolling Biologics License Application for Teplizumab in Q4 2020 -
-
May 5, 2020Objective responses seen in 29% of patients with locally advanced basal cell carcinoma (BCC)